HRT after early menopause: why the blood test comes before the prescription

A woman in her early fifties, post menopausal for seven years after IVF treatment, sits down in clinic and asks for hormone replacement therapy. She has researched the options. She wants the transdermal route. She has been managing for years without treatment and has come in now because the mood swings, the broken sleep, and the central weight gain are no longer something she can keep ignoring. The right answer is not a same day prescription. The right answer is a two visit decision: a structured baseline blood set today, and the prescription written next week, after the result. This article walks through why.

Why HRT prescribing is two visits, not one

HRT is a real treatment with real benefits and real risks. Done well, it eases the menopausal symptom load, supports bone density over the years that matter, and gives the patient back the energy and the steady mood that the menopausal transition has taken away. Done badly, it increases the small absolute risk of breast and ovarian cancer over time, and it raises the risk of venous thromboembolic disease, that is, blood clots in the legs and the lungs.

The decision about which preparation to start, and at what dose, is informed by the patient’s bloods. We want to know the haemoglobin, the iron stores, the thyroid function, the hormone profile, the cholesterol, and the diabetes screen. None of those numbers are unreasonable to ask for before a year of daily medication. All of them inform the choice of preparation and the safety net that goes with it.

The structured two visit approach is not delay for delay’s sake. It is the floor under the prescription.

The transdermal route, and why it matters

HRT can be given as oral tablets or as a transdermal patch. The oestrogen molecule is the same in both. The route makes a difference because the transdermal route bypasses the first pass through the liver. That single fact changes the clot risk profile.

The oral route raises the risk of venous thromboembolic disease in a way that the transdermal route, at standard doses, does not. For most women considering HRT, this is the single most important practical reason to choose the patch over the tablet. It does not eliminate clot risk. It changes the order of magnitude.

For a woman who has had pregnancy related hypertension in the past, or who has a family history of blood clots, the transdermal route is often the obvious choice. The patch is changed twice a week. It can be stopped immediately if there is a problem. Most patients tolerate it without skin irritation; the small minority who do can switch to a different brand.

The progesterone piece, when the womb is in place

If the patient has not had a hysterectomy, oestrogen alone is not safe. Long term unopposed oestrogen exposure in a patient with a womb increases the risk of endometrial cancer. The fix is straightforward: a daily progesterone is given alongside the oestrogen.

The progesterone can come as a tablet taken every day, as a daily transdermal patch (a combined patch contains both hormones), or as an intrauterine device that delivers the progesterone locally. For a patient who prefers patches and prefers to avoid daily tablets, the combined transdermal patch is the practical answer. We can talk through which preparation suits the patient’s pattern at the second visit.

The baseline blood set, what we order and why

A typical baseline before starting HRT includes a full blood count, ferritin, vitamin B12, thyroid function, a hormone panel (follicle stimulating hormone, oestradiol, progesterone, prolactin), a cholesterol profile, and HbA1c for diabetes screening. The list is not exotic. It is the standard floor.

The hormone panel is helpful even when the patient is clearly post menopausal because it confirms the picture and rules out anything atypical. The thyroid function matters because thyroid disease can mimic menopausal symptoms and is easily missed. The cholesterol and the HbA1c matter because the menopausal transition is also the time at which cardiovascular risk shifts; a baseline is useful even if no medication is started for it.

The risks worth naming honestly

The breast cancer risk on long term combined HRT is increased, but the absolute increase is small for most women. The ovarian cancer risk is also slightly raised on long term use. Both numbers are smaller than the patient often imagines and the honest conversation in the room reduces the catastrophic framing that the headlines often produce.

The clot risk on the transdermal route at standard doses is not raised meaningfully above background. The clot risk on the oral route is raised. That single fact informs most prescribing decisions today.

The benefit on bone density is real and important; many fractures in older age are prevented by years on HRT during the perimenopausal and early post menopausal window. The benefit on mood, sleep, and the vasomotor symptoms (the hot flushes, the night sweats) is real and often life changing.

The non hormonal alternatives, when HRT is not the right fit

Some patients prefer to avoid HRT for personal or clinical reasons. The non hormonal options have a real but modest evidence base. A herbal category preparation can help with vasomotor symptoms in some patients. Certain antidepressant categories, used off label, can help with mood and with hot flushes for patients in whom HRT is contraindicated.

None of these are equivalent to HRT in symptom control, but for the right patient they are reasonable. The honest conversation walks through the trade off, makes the patient’s preference the centre, and offers the structured plan rather than a default.

The safety net once on HRT

Every patient on HRT leaves the clinic with a clear safety net. New calf swelling, especially with redness or warmth, is a clot until proven otherwise and warrants same day assessment. Sudden chest pain or breathlessness needs hospital. New lumps in the breast warrant urgent review. Post menopausal bleeding, once on a continuous combined preparation, warrants assessment with a low threshold.

None of these are scare tactics. They are the standard safety net that makes HRT a safe long term treatment when followed.

Why same day private GP for this conversation

An NHS GP appointment for HRT can be excellent. It can also be a five minute slot in which the patient leaves with a prescription before the conversation has happened. A 30 minute private consultation, with same day access, gives the room to take the history properly, talk through the route, name the alternatives, order the structured baseline blood set, and book the second visit for the prescribing decision.

If you are considering HRT, or if you have already started and want a second opinion on the preparation and the dose, book a same day Clinique Alpa appointment and we will hold the room for the structured two visit decision.